Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CML 2022 | Measuring residual disease in granulocytes to predict relapse after therapy cessation in CML

Ilaria Pagani • 21 Oct 2022
ESH CML 2022
Chronic Myeloid Leukemia Leukemia

Ilaria Pagani, PhD, University of Adelaide, Adelaide, Australia, comments on the monitoring of residual disease in patients with chronic myeloid leukemia (CML) to detect relapse after therapy cessation using a novel sensitive method. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Ilaria Pagani

1:14
The importance of patients' involvement in CML research
Ilaria Pagani • 21 Oct 2022

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals